For the active substance fluroxypyr, the Authority needs additional time to conclude the risk assessment carried out for the substance, including, where appropriate, a public consultation and a consultation of experts. Additional time is also necessary for the Commission to adopt the ensuing risk management decision.
Recital 8, Regulation (EU) 2024/2781
In forcesince 31 Oct 2024